Replacing lost tissue, growing cells and developing organs that can restore function.
Cell survival, functional output and clinical benefit require their own measurements.
Each dossier describes the mechanism, studies and development history of a research programme.
2 programmes and 1 article in this edition.
LyGenesis
LyGenesis transplants donor liver cells into abdominal lymph nodes, where it aims to grow auxiliary liver tissue. Human testing began in 2024. A subsequent safety review supported continuation, while detailed human efficacy results remain unverified in the sources checked.
eGenesis
eGenesis engineers pig kidneys to address immune incompatibility and pathogen risks in transplantation. Expanded access has supplied early human evidence. A formal trial remains a planned next step, with its proposed start distinguished from the evidence already reported.
Zimislecel and UP421 test cell replacement in type 1 diabetes. Zimislecel has produced insulin independence in a small study with immunosuppression. UP421 tests whether edited donor cells can survive without it.
Read article